Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.
Journal Information
Full Title: Diabetes Metab Syndr Obes
Abbreviation: Diabetes Metab Syndr Obes
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Endocrinology & Metabolism
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosures: Dr Vella has received grant support from Merck in the past year. The studies examining the mechanism of action of vildagliptin and commented on in this paper were investigator-initiated studies funded by Novartis. He has consulted for Sanofi-Aventis and CPEX Pharmaceuticals. Dr Smushkin reports no conflicts of interest in this work."
"Disclosures: Dr Vella has received grant support from Merck in the past year. The studies examining the mechanism of action of vildagliptin and commented on in this paper were investigator-initiated studies funded by Novartis. He has consulted for Sanofi-Aventis and CPEX Pharmaceuticals. Dr Smushkin reports no conflicts of interest in this work."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025